Dr. Raymond Turner appointed as Integra's new VP and CMO, enhancing medical affairs and clinical development initiatives.
Quiver AI Summary
Integra LifeSciences Holdings Corporation has appointed Dr. Raymond Turner as its new corporate vice president and chief medical officer, effective September 22, 2025. With over 20 years of experience in clinical operations and leadership roles at major MedTech companies, Dr. Turner will oversee worldwide medical affairs and clinical development at Integra. He will also continue his clinical practice in neurosurgery. CEO Mojdeh Poul emphasized Dr. Turner's expertise in advancing safety and quality as crucial for Integra's mission to improve patient care through robust clinical evidence. Dr. Turner has a significant background in research and has published extensively, further underscoring his suitability for the role.
Potential Positives
- Dr. Raymond Turner's appointment as corporate vice president and chief medical officer brings over 20 years of clinical operations experience, enhancing Integra's leadership team and credibility in the MedTech industry.
- His expertise in clinical research and evidence generation aligns with Integra's focus on building robust clinical evidence to support innovative solutions and improve patient care.
- Dr. Turner's ongoing clinical practice will ensure that Integra's product development remains closely aligned with real-world medical needs and patient outcomes.
- The appointment has been positively received by company leadership, indicating strong confidence in Dr. Turner's ability to advance the company’s mission and enhance its reputation in the healthcare sector.
Potential Negatives
- The announcement of a new chief medical officer may imply a prior vacancy in this crucial role, which could raise concerns about leadership continuity and strategic direction within the company.
- Dr. Raymond Turner will continue his clinical practice while serving as CMO, which may lead to potential conflicts of interest or questions about his availability and dedication to Integra's initiatives.
- Details regarding the specific challenges or issues that prompted the need for a new chief medical officer were not disclosed, leaving ambiguity around current operational effectiveness.
FAQ
Who is Dr. Raymond Turner?
Dr. Raymond Turner is the new corporate vice president and chief medical officer of Integra LifeSciences, bringing over 20 years of clinical experience.
What will Dr. Turner’s role at Integra involve?
Dr. Turner will lead worldwide medical affairs and clinical development activities, including clinical research and safety communications.
What experience does Dr. Turner have in the MedTech industry?
Dr. Turner has held senior leadership roles at Siemens Healthineers and Cerenovus, contributing to significant advancements in medical technology.
How many publications has Dr. Turner authored?
Dr. Turner has authored over 150 peer-reviewed publications and has participated in more than 70 research studies.
What is the mission of Integra LifeSciences?
Integra LifeSciences is dedicated to restoring patients' lives through innovative treatment pathways and high-quality medical technologies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IART Hedge Fund Activity
We have seen 110 institutional investors add shares of $IART stock to their portfolio, and 132 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP added 2,710,262 shares (+58.4%) to their portfolio in Q2 2025, for an estimated $33,254,914
- ALLIANCEBERNSTEIN L.P. removed 2,626,194 shares (-97.0%) from their portfolio in Q2 2025, for an estimated $32,223,400
- WELLINGTON MANAGEMENT GROUP LLP removed 1,442,357 shares (-52.1%) from their portfolio in Q2 2025, for an estimated $17,697,720
- LORD, ABBETT & CO. LLC removed 1,328,701 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $16,303,161
- MORGAN STANLEY removed 876,770 shares (-18.2%) from their portfolio in Q2 2025, for an estimated $10,757,967
- CAPITAL RESEARCH GLOBAL INVESTORS removed 825,742 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,131,854
- DEERFIELD MANAGEMENT COMPANY, L.P. added 794,865 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,752,993
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IART Analyst Ratings
Wall Street analysts have issued reports on $IART in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 05/09/2025
- JP Morgan issued a "Underweight" rating on 05/06/2025
- Argus Research issued a "Buy" rating on 03/31/2025
To track analyst ratings and price targets for $IART, check out Quiver Quantitative's $IART forecast page.
$IART Price Targets
Multiple analysts have issued price targets for $IART recently. We have seen 4 analysts offer price targets for $IART in the last 6 months, with a median target of $16.0.
Here are some recent targets:
- David Turkaly from JMP Securities set a target price of $25.0 on 05/09/2025
- Robbie Marcus from JP Morgan set a target price of $12.0 on 05/06/2025
- Vik Chopra from Wells Fargo set a target price of $13.0 on 05/06/2025
- Richard Newitter from Truist Securities set a target price of $19.0 on 04/11/2025
Full Release
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Dr. Raymond Turner as its new corporate vice president and chief medical officer.
Dr. Turner brings more than 20 years of experience in clinical operations, having held senior leadership positions at some of the world’s largest global MedTech companies. At Integra, Dr. Turner will lead worldwide medical affairs and clinical development activities including clinical research, clinical trial operations, evidence generation, medical safety and communications. In addition to his role with Integra, Dr. Turner will continue his clinical practice, providing patients with neurosurgical care.
“Dr. Turner’s extensive medical and clinical experience and expertise will be significant assets to Integra as we strengthen our focus on building robust clinical evidence,” said Mojdeh Poul, president and chief executive officer, Integra LifeSciences. “His proven leadership and passion for advancing safety and quality will help us continue to deliver innovative solutions and transform patient care for the millions around the world.”
Prior to joining Integra, Dr. Turner held various leadership roles at Siemens Healthineers, including his most recent position as the chief medical officer for Siemens Endovascular Robotics. Prior to this, he was a medical director for Cerenovus, a Johnson & Johnson MedTech company. Additionally, Dr. Turner served as the program director of the neurosurgery residency program and was the chief of neuroscience (neurological surgery, neurology, and ENT) at the Medical University of South Carolina.
“I am excited to be joining Integra, an organization deeply committed to providing best-in-class, evidence-based products that help restore patient lives,” said Dr. Raymond Turner. “I look forward to working closely with both the Integra team and our healthcare partners to improve patient outcomes and uphold the highest standards of care.”
Dr. Turner served as a practicing surgeon at PRISMA Health and most recently, at Intermountain Health in Billings, Montana. He currently serves as an examiner for the American Board of Neurological Surgery.
Dr. Turner completed his undergraduate degree in biology at Sacred Heart University in Connecticut. He obtained his medical degree at Karol Marcinkowski University of Medical Sciences in Poznan, Poland. Dr. Turner completed his residency in neurological surgery and his fellowship in endovascular neurosurgery at the Cleveland Clinic. He has authored more than 150 peer-reviewed publications and has been involved in more than 70 pre-clinical and clinical research studies.
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com .
Investor Relations:
Chris Ward
(609) 772-7736
[email protected]
Media:
Laurene Isip
(609) 208-8121
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d1bd1b51-a9bb-4545-b463-a79108abf93f
